Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
2009 · Cancer Cell · 825 citations
https://doi.org/10.1016/j.ccr.2009.03.020
T
Teemu T. Junttila
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
100
Papers
5.5K
Citations
28
h-index
33
i10-index
Teemu T. Junttila is an academic researcher. The author has contributed to research in topics: Monoclonal and Polyclonal Antibodies Research & CAR-T cell therapy research & HER2/EGFR in Cancer Research. The author has an h-index of 28, co-authored 85 publications.
ORCID: 0000-0001-9936-2420Papers by this author
worksMembrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing
2017 · Cancer Cell · 289 citations
https://doi.org/10.1016/j.ccell.2017.02.001
Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer
2004 · Molecular Cancer Therapeutics · 268 citations
https://doi.org/10.1158/1535-7163.1585.3.12
Signaling via ErbB2 and ErbB3 Associates with Resistance and <i>Epidermal Growth Factor Receptor</i> (<i>EGFR</i>) Amplification with Sensitivity to EGFR Inhibitor Gefitinib in Head and Neck Squamous Cell Carcinoma Cells
2006 · Clinical Cancer Research · 255 citations
https://doi.org/10.1158/1078-0432.ccr-05-2404
Superior <i>In vivo</i> Efficacy of Afucosylated Trastuzumab in the Treatment of HER2-Amplified Breast Cancer
2010 · Cancer Research · 216 citations
https://doi.org/10.1158/0008-5472.can-09-3704
ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease.
2002 · PubMed · 186 citations
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat